Table 3.
Tigecycline susceptibilities of various antimicrobial-resistant isolates, obtained from 2006 to 2010, determined by the broth microdilution method
| Bacterium(a) (no. of isolates) | Range | MIC (μg/ml) |
% of isolates categorized by: |
||||||
|---|---|---|---|---|---|---|---|---|---|
| FDA MIC interpretive criteria |
EUCAST-2011 MIC interpretive criteria |
||||||||
| MIC50 | MIC90 | Susceptible | Intermediate | Resistant | Susceptible | Intermediate | Resistant | ||
| MRSA (1,834) | 0.03–1 | 0.125 | 0.5 | 100 | NAa | NA | 100 | NA | 0 |
| PRSP (423) | 0.008–0.06 | 0.016 | 0.03 | 100 | 0 | 0 | NA | NA | NA |
| VRE (219) | 0.016–1 | 0.03 | 0.125 | 98.6 | 0 | 0 | 98.6 | 0.9 | 0.5 |
| ESBL-producing E. coli (1,141) | 0.03–8 | 0.25 | 0.5 | 99.6 | 0.3 | 0.1 | 98.7 | 1.0 | 0.3 |
| ESBL-producing K. pneumoniae (1,330) | 0.125–16 | 0.5 | 2 | 96.3 | 2.9 | 0.8 | 85.8 | 10.5 | 3.7 |
| A. baumannii (1,645) | 0.03–64 | 2 | 4 | 68.2 | 23.1 | 8.8 | 35.0 | 33.1 | 31.9 |
| S. maltophilia (903) | 0.03–16 | 2 | 4 | NA | NA | NA | NA | NA | NA |
a
NA, MIC interpretive breakpoint for tigecycline was not available.